Peer-reviewed veterinary case report
Domperidone effects on antibodies and kidney markers in dogs
By Cavalera, Maria Alfonsa et al.·Published in Parasites & vectors·2021·Department of Veterinary Medicine, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of domperidone (leisguard®) on antibody titers, inflammatory markers and creatinine in dogs with leishmaniosis and chronic kidney disease.
- Species:
- dog
Plain-English summary
A group of dogs with leishmaniosis (a disease caused by a parasite) and chronic kidney disease (CKD) were treated with an oral medication called domperidone. Over six months, nine out of fourteen dogs showed a significant improvement in kidney function, as indicated by lower creatinine levels. Additionally, all dogs had reduced levels of antibodies related to the parasite, as well as lower inflammatory markers in their blood. These results suggest that domperidone may help manage both leishmaniosis and kidney issues in affected dogs.
People also search for: dog leishmaniosis treatment · chronic kidney disease in dogs · domperidone for dogs kidney disease
Abstract
BACKGROUND: Immunotherapeutic drugs, such as domperidone, have been shown to be promising treatments against canine leishmaniosis (CanL), but limited data are available. The aim of this pilot study (therapeutic, prospective and non-controlled) was to evaluate the effect of domperidone on serum antibody titers of Leishmania infantum, globulins, gamma globulins, acute-phase proteins (e.g. C-reactive protein [CRP]), big endothelin-1 (big ET-1), serum creatinine (SC) and proteinuria in dogs with leishmaniosis affected by chronic kidney disease (CKD). METHODS: Dogs were recruited if "exposed" to or "infected" with L. infantum and affected by CKD (IRIS stage 1 [proteinuric] or IRIS stage 2-3a [SC < 3.5 mg/dl; proteinuric or non-proteinuric]). After inclusion, an oral suspension of domperidone was administered, and the dogs were followed up for 180 days, with checks at 30, 60, 90 and 180 days after initial treatment. RESULTS: Of the 14 recruited dogs, nine showed a statistically significant reduction in SC (χ = 9.1, df = 3, P = 0.028), but not in the urine protein/creatinine ratio (χ = 6.43, df = 3, P = 0.092). All dogs showed a significant reduction in antibody titers for L. infantum (χ = 9.56, df = 2, P = 0.008), globulins (χ = 11.08, df = 3, P = 0.011) and gamma globulins (χ = 12.38, df = 3, P = 0.006) during the study period. There was also a statistically significant reduction in CRP (χ = 16.7, df = 3, P = 0.001), but not in big ET-1 (χ = 2.04, df = 3, P = 0.563). CONCLUSIONS: This study provides preliminary results on the ability of domperidone to improve SC and reduce anti-L. infantum antibody titers, globulins, gamma globulins and CRP in dogs with leishmaniosis and CKD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34629081/